Celator commences third phase of leukemia study CPX-351
News | 27 December 2012
Celator Pharmaceuticals has commenced patient enrollment in the phase-III study of CPX-351 in untreated high-risk acute myeloid leukemia (AML). The open-label trial is designed to assess CPX-351 (cytarabine:daunorubicin) liposome injection compared to ...
Click on the link to read the full article at Pharmaceutical Business Review
(This link will open in a new window)
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
